-SDS-PAGE of antibody-dye conjugates and free dye. After reaction and purification all conjugates were run on SDS-PAGE and scanned on the Odyssey CLx NIR scanner to ensure free dye was removed. Window leveling adjusted for similar brightness from heavy chain. Tras, trastuzumab; Bev, bevacizumab. Figure S3 -SDS-PAGE of serum stability samples. Serum stability samples show intact antibody out to 17 days and no detectable formation of free dye. Figure S4 -Antibody-dye conjugate serum stability. Both Tras-AF680 and Tras-800CW show slight loss in fluorescence over 17 days (80% and 60% of initial, respectively); however, the loss in fluorescence does not account for the rapid drop in fluorescent signal seen with 800CW in Fig. 2 . Therefore, the loss of fluorescent signal in Fig. 2 is due to clearance of the antibody-dye conjugate, not loss of fluorescence from the dye being in serum. Tras-AF680 and Tras-800CW, both with a DoL of 1.2, were mixed with fetal bovine serum (FBS) at 30nM. The serum/antibody-dye aliquots were thawed rapidly in a 37°C water bath and incubated at 37°C for the number of days shown. The samples were thawed and placed at 37°C in reverse order (17 day time point first) so the samples could all be measured on the same day. 15 µL of each sample was scanned in a 384 well plate on the Odyssey CLx, and the experiment was performed in triplicate. Before further processing for biodistribution, whole organs were scanned on the Odyssey Clx. Qualitatively the signal intensity from organ scans matches the quantitative uptake from biodistributions (Fig. 5) . Window leveling is the same for each channel. Li, liver; Lu, lung; K, kidneys; S, spleen; H, heart; M, muscle; P, pancreas. Tras, trastuzumab; Bev, bevacizumab; F, fluorescence; E, ELISA. Note: These data (*) were published in the supplementary data section (Fig. S7 ) of 1
